États-Unis · Plateformes & données · Seeking Alpha

Co-Diagnostics outlines India TB submission with ~97.3% sensitivity and ~96% specificity as $6.2M Q3 operating expenses decline 12%

Publié par Seeking Alpha · États-Unis il y a 4 h

Résumé détaillé

Co-Diagnostics submits its CoSara TB test to India’s CDSCO after 97.3% sensitivity and 96% specificity; its Flu A/B/RSV filing remains under FDA review.

Lire l'article complet sur Seeking Alpha Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (seekingalpha.com)

Co-Diagnostics outlines India TB submission with ~97.3% sensitivity and ~96% specificity as $6.2M Q3 operating expenses decline 12%

Résumé détaillé

À lire aussi

D-Wave Quantum: 3 Key Takeaways for Long-Term Investors

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

World leaders to address COP31 as Turkey pushes for new climate deal

ONDS Stock Rises Overnight: Ondas Scores New ‘Digital Bat’ Drones Order Ahead Of Earnings

Desane signs $14.5 million Penrith construction contract

Giant toilet paper supplier files Chapter 11 bankruptcy

Co-Diagnostics outlines India TB submission with ~97.3% sensitivity and ~96% specificity as $6.2M Q3 operating expenses decline 12%

Résumé détaillé

Partager

À lire aussi

D-Wave Quantum: 3 Key Takeaways for Long-Term Investors

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

World leaders to address COP31 as Turkey pushes for new climate deal

ONDS Stock Rises Overnight: Ondas Scores New ‘Digital Bat’ Drones Order Ahead Of Earnings

Desane signs $14.5 million Penrith construction contract

Giant toilet paper supplier files Chapter 11 bankruptcy